2021-03-05 04:35:50 GMT2021-03-05 12:35:50(Beijing Time) Xinhua English
ANKARA, March 5 (Xinhua) Turkey announced on Wednesday that the China-developed Sinovac vaccine has an efficacy of 83.5 percent against COVID-19, furthering the country s confidence in winning the fight against the pandemic.
The CoronaVac shot developed by Sinovac Biotech was 100 percent effective in preventing hospitalization, according to the Phase-3 trials by the Hacettepe University in Ankara, the semi-official Anadolu Agency reported.
No major side effects have been reported, professor Murat Akova from the university who led the trials, told reporters during a press conference.
He added that the antibody levels were predicted to reach their maximum between 14 and 28 days after the second dose.
World Insights: Turkey s confidence in China-developed COVID-19 vaccine strengthens_GMW cn en.gmw.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from en.gmw.cn Daily Mail and Mail on Sunday newspapers.
Daily briefing on novel coronavirus pandemic worldwide, Turkey, other developments Seda Sevencan | 04.03.2021
ANKARA
Anadolu Agency is here with a rundown of the latest developments on the coronavirus pandemic and other news in Turkey and around the world.
Coronavirus and other developments in Turkey
With the latest cases, the country s overall caseload surpassed 2.73 million and the tally of fatalities stands at 28,771 after 65 people died over the past 24 hours, according to Health Ministry data.
As many as 7,191 people won their battle against the disease, bringing the number of recoveries to near 2.6 million.
In a statement on the latest results of Phase 3 trials in Turkey of the Chinese-made Sinovac vaccine, Health Minister Fahrettin Koca said its overall efficiency was 83.5% with a hospitalization prevention rate of 100%.
Turkish guides took virus measures faster than EU peers yenisafak.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yenisafak.com Daily Mail and Mail on Sunday newspapers.